Here are the results of the OTC Children's Medications poll.
PharmTech Poll Results: OTC Children’s Medications
The question:
The US Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee recently recommended that over-the-counter cough and cold medications not be given to children under age 6 based on their conclusion that the drugs have not been proven effective according to current research and there is a risk of adverse effects. The committees further recommended that dosing devices be required and standardized using volume measurements for liquid formulations.
Do you agree with the committees that there should be standardized dosing devices for all OTC children’s medications?
Your Answers:
Thanks to all of you who participated in our poll! All respondants agreed that OTC children’s medications should have standardized dosing devices.
One person commented, “These should be sold directly by the pharmacist like the pseudoephedrine formulations so the parents administering the doses understand how to use the dosing device and to make sure the patient is not taking other medication that could impact the dosing.”
To add your comments, click here.
For more on this topic, see:
Wyeth Recalls Cold Medicines, Lawmakers Urge FDA Action
FDA Committees Recommend Ban on Cough and Cold Medications for Young Children
Drug Makers Voluntarily Recall OTC Infant Cough and Cold Medications
FDA to Discuss Pediatric OTC Drugs, Warns Against Codeine Use
To see the results of our previous polls, see the poll archive.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.